Annexon

Annexon CROIC

The Cash Return on Invested Capital (CROIC) of Annexon (ANNX) as of Nov 3, 2026 is -86.92 %. In the previous year, Cash Return on Invested Capital (CROIC) was -40.27 % — a change of 115.87% (lower).

CROIC

-86.92 %

YoY

115.87%

Last updated:

Cash Return on Invested Capital (CROIC) of Annexon is 2025 -86.92 % . Cash Return on Invested Capital (CROIC) of Annexon was 2024 -40.27 % . It decreases by 115.87% lower compared to the previous year.

The Annexon CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-45.43 USD
Jan 1, 2019
-65.76 USD
Jan 1, 2020
-15.55 USD
Jan 1, 2021
-46.47 USD
Jan 1, 2022
-53.13 USD
Jan 1, 2023
-48.43 USD
Jan 1, 2024
-40.27 USD
Jan 1, 2025
-86.92 USD
The Annexon CROIC history
YEARCROICYoY
-86.92 %+115.87%
-40.27 %-16.85%
-48.43 %-8.85%
-53.13 %+14.34%
-46.47 %+198.74%
-15.55 %-76.35%
-65.76 %+44.76%
-45.43 %-205.87%
42.91 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Annexon Stock analysis

What does Annexon do? Annexon Inc is a biopharmaceutical company based in South San Francisco, California. It was founded in 2011 by Doug Love, Ted Love, and Arnon Rosenthal, who had previously worked at major pharmaceutical companies such as Genentech and Novartis. The company's main goal is to develop new treatment options for neurodegenerative diseases, focusing on the development of drugs that target the autophagy process in cells to reduce damage to nerve cells and alleviate symptoms. Annexon Inc has two divisions, Annexon Biosciences and Annexon Clinical, with partnerships with renowned pharmaceutical companies to advance drug development. Its main product is ANX005, a therapeutic antibody protein that targets the role of the complement system in neurodegenerative diseases. Annexon Inc has received multiple awards for its work and innovations and has a dedicated team of scientists and executives committed to improving the lives of people with neurodegenerative diseases. Annexon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Annexon stock

Cash Return on Invested Capital (CROIC) of Annexon is -86.92 % in 2025.

Cash Return on Invested Capital (CROIC) of Annexon changed from -40.27 % to -86.92 %, representing a 115.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Annexon since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Annexon with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Annexon

All Key Metrics — Annexon